Based in Cambridge, UK, we are making better medicines by continually improving our antibody discovery technologiesLearn more
Our unique technologies drive the rapid development of effective, human antibody-based drugs across our four main therapeutic areas - immuno-oncology, inflammation, haematology and infectious disease.View our pipeline
Join us in developing tomorrow's medicines: we're driven by passion for better healthcare and by compassion to make a difference. Join our experienced and successful team and help us to realise our aims.View our vacancies
Kymab, is included in the 2020 Sunday Times Sage Tech Track 100, which ranks Britain’s 100 private tech (TMT) companies with the fastest-...
Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases a...
Landmark UK Supreme Court decision invalidates Regeneron Patent claims
Cambridge, UK; 22 June 2020: Kymab, a clinical-stage biopharmaceutical company developing antibody-based therapeutics, today announced th...
10 Nov 2020 - 14 Nov 2020 | Gaylord National Hotel & Convention Center, Washington, USA
View event details